The Potential of Dapagliflozin Plus Exenatide in Obese Insulin-resistant Patients

NCT03419624 on ClinicalTrials.gov · last registry update 2020-03-31

Stopped early, having planned 13 participants. The sponsor logged completion for 1 April 2019. Primary outcome, as filed: Change in HbA1c from baseline (week 0) to week 28. exenatide is approved in the US, but not for obesity — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: TERMINATED
Phase: P3
Drug: exenatide
Bydureon, Byetta
Sponsor: Universitätsklinikum Hamburg-Eppendorf
Sponsor type: Other
Enrollment: 13
Started: 2018-02-19
Primary completion: 2019-04-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in HbA1c from baseline (week 0) to week 28

Conditions studied

Obesity · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the exenatide page for this molecule’s full trial and approval history.